Tetrahydrofuran

Tetrahydrofuran

SCHEMBL3294902

C1CCOC1.C1CCOC1.O=C(O)O

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Tetrahydrofuran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.61
CA1 P00915 2/20 0.39
CA9 Q16790 2/20 0.39
GLA P06280 1/20 0.39
CA2 P00918 1/20 0.39
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
TP53 P04637 1/20 0.38
HSD17B10 Q99714 1/20 0.36
TTR P02766 1/20 0.36
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.33
CA12 O43570 1/20 0.33
PKM P14618 1/20 0.31
MMP1 P03956 1/20 0.31
MMP3 P08254 1/20 0.31
MMP8 P22894 1/20 0.31
KDM4E B2RXH2 1/20 0.31
FKBP1A P62942 1/20 0.30
KMO O15229 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrahydrofuran SCHEMBL16166505 1.00 ALDH1A1 (0.61) ALDH1A1CA1CA9GLACA2
Tetrahydrofuran SCHEMBL905739 1.00 ALDH1A1 (0.61) ALDH1A1CA1CA9GLACA2
Tetrahydrofuran SCHEMBL1950354 1.00
Tetrahydrofuran SCHEMBL11210398 0.96 ALDH1A1 (0.57) ALDH1A1CA1CA9GLACA2
Bicarbonate SCHEMBL28647212 0.96 ALDH1A1 (0.57) ALDH1A1CA1CA9GLACA2
Bicarbonate SCHEMBL5550742 0.96 ALDH1A1 (0.57) ALDH1A1CA1CA9GLACA2
Bicarbonate SCHEMBL8169227 0.96 ALDH1A1 (0.57) ALDH1A1CA1CA9GLACA2
Bicarbonate SCHEMBL3145335 0.93 ALDH1A1 (0.53) ALDH1A1CA1CA9GLACA2
Tetrahydrofuran SCHEMBL8590475 0.93 ALDH1A1 (0.53) ALDH1A1CA1CA9GLACA2
Oxalic Acid SCHEMBL30284941 0.89 ALDH1A1 (0.57) ALDH1A1CA1CA9GLAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111278357-B Synthetic film composition comprising polyurethane and polyoxazoline 帝斯曼知识产权资产管理有限公司 2023-10-31 CN disclosed
CN-115697254-A Medical implant for cartilage replacement and method for producing such an implant 帝斯曼知识产权资产管理有限公司 2023-02-03 CN disclosed
CN-111278358-B Synthetic membrane compositions comprising fluorinated polyurethanes 帝斯曼知识产权资产管理有限公司 2022-10-28 CN disclosed
CN-113518634-B Radiopaque medical assemblies and devices 帝斯曼知识产权资产管理有限公司 2022-09-27 CN disclosed
CN-113518634-A Radiopaque medical assemblies and devices 帝斯曼知识产权资产管理有限公司 2021-10-19 CN disclosed
CN-111278358-A Synthetic membrane compositions comprising fluorinated polyurethanes 帝斯曼知识产权资产管理有限公司 2020-06-12 CN disclosed
CN-111278357-A Synthetic membrane compositions comprising polyurethane and polyoxazoline 帝斯曼知识产权资产管理有限公司 2020-06-12 CN disclosed
CN-106928247-A Spiral shell oxindole compounds and its purposes as therapeutic agent 泽农医药公司 2017-07-07 CN disclosed
CN-103664973-B Spiro-oxindole compounds and their use as therapeutic agents 泽农医药公司 2017-04-19 CN disclosed
CN-102256983-B Spirooxindole compounds and their use as therapeutic agents 泽农医药公司 2017-04-05 CN disclosed
EP-2069303-B1 ANTIVIRAL PROTEASE INHIBITORS GILEAD SCIENCES INC (US) 2016-03-30 EP disclosed
US-7723380-B2 Tetrahydrofuro[2,3-b]furyl carbamates containing an (oxy)hydrazide group; these compounds target the HIV protease in both wild type and mutant strains of HIV. GILEAD SCIENCES, INC. (US) 2010-05-25 US disclosed
US-20090306112-A1 ANTIVIRAL PROTEASE INHIBITORS GILEAD SCIENCES, INC. (US) 2009-12-10 US disclosed
EP-2069303-A2 ANTIVIRAL PROTEASE INHIBITORS Gilead Sciences, Inc. (US) 2009-06-17 EP disclosed
US-20090105279-A1 Antiviral protease inhibitors GILEAD SCIENCES, INC. 2009-04-23 US disclosed
WO-2008011117-A2 ANTIVIRAL PROTEASE INHIBITORS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed
CN-1333580-A Non-aqueous electrochemistry device MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) 2002-01-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105279-A1 Antiviral protease inhibitors ACE, TMPRSS15, MME ALDH1A1 3629/4885CA1 1565/4885CA9 1115/4885
US-20090306112-A1 ANTIVIRAL PROTEASE INHIBITORS ACE, DNPEP, TMPRSS15 ALDH1A1 3653/4885CA1 1590/4885CA9 1103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.